
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx is well-positioned in the biopharmaceutical industry with a promising drug pipeline, strong financial projections, and a potential blockbuster drug in Ibsrela. With positive results from clinical trials and a strong patent portfolio, the company has the potential for significant growth and could become a major player in the market. The future success of Ibsrela and Xphozah will be key drivers of Ardelyx's growth, making it an attractive investment option for those with a long-term view.
Bears say
Ardelyx is facing challenges in achieving its revenue goals for Ibsrela and Xphozah, with only moderate increases in R&D and SG&A expenses predicted for FY26 and its target price remaining unchanged at $19. Despite being the only sodium transport inhibitor in two approved indications, the drug faces significant competition and pricing pressures in a complex and price-sensitive commercial market. Additionally, there is still considerable unmet need in both target diseases, suggesting a lack of widespread demand or success for the drug.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares